CD8A and myeloid sarcoma: As with CD4+ Treg, a recent meta-analysis clearly showed a significant reduction in the number of CD8+ Treg in MS patients [39], and the frequency of circulating CD8+FoxP3+ T cells was significantly lower in the peripheral blood of MS patients during relapse than when they were in remission [40].